Jazz Pharmaceuticals stock climbs after positive Phase 3 cancer drug results

Investing.com -- Jazz Pharmaceuticals (NASDAQ:JAZZ) stock surged 25% after the company announced positive Phase 3 trial results for its cancer drug Ziihera in treating gastroesophageal cancer.

The Dublin-based biopharmaceutical company reported that both Ziihera plus chemotherapy and Ziihera plus Tevimbra and chemotherapy demonstrated statistically significant improvements in progression-free survival compared to the current standard treatment of trastuzumab plus chemotherapy.

The HERIZON-GEA-01 trial evaluated Ziihera (zanidatamab-hrii) as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The Ziihera plus Tevimbra and chemotherapy combination also showed statistically significant improvements in overall survival, while Ziihera with chemotherapy demonstrated "a clinically meaningful effect with a strong trend toward statistical significance" for overall survival.

Dr. Kohei Shitara, principal trial investigator at Japan’s National Cancer Center Hospital East, noted that the results suggest Ziihera combinations have "the potential to become the new standard of care" for patients with HER2-positive first-line gastroesophageal cancer.

The trial enrolled 914 patients across approximately 300 sites in more than 30 countries. Jazz plans to submit a supplemental Biologics License Application to the FDA in the first half of 2026 for Ziihera in this indication.

The company will present detailed data at a medical meeting in Q1 2026 and submit the findings to a peer-reviewed journal. The safety profile was consistent with known profiles of each agent with no new safety signals observed.

This marks the first Phase 3 trial results for Ziihera, which is also being studied in other cancer types including biliary tract cancer and breast cancer.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.